Regulatory effect and mechanism of macrophage polarization in liver fibrosis

Xiaoyang BAI; Xu ZHANG; Long HAI; Xiangchun DING

doi:10.12449/JCH240329

Volume 40 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(3): 611-615

PDF( 684 KB)

Regulatory effect and mechanism of macrophage polarization in liver fibrosis

DOI: 10.12449/JCH240329

Xiaoyang BAI^{1a, 1b, 2},
Xu ZHANG^1b,
Long HAI^1a,
Xiangchun DING^{1a
,
,
,}

1a.
Department of Infectious Diseases，Academy of Medical Sciences，General Hospital of Ningxia Medical University，Yinchuan 750000，China
1b.
Department of Surgery，Academy of Medical Sciences，General Hospital of Ningxia Medical University，Yinchuan 750000，China
2.
School of Clinical Medicine，Ningxia Medical University，Yinchuan 750000，China

Research funding:

Ningxia Natural Science Foundation (2023AAC03584);

Ningxia Natural Science Foundation (2023AAC03519)

More Information

Corresponding author: DING Xiangchun， 13619511758@163.com （ORCID： 0000-0003-0283-9419）
Received Date: 2023-08-10
Accepted Date: 2023-11-10
Published Date: 2024-03-20

Abstract

Abstract

Liver fibrosis is the healing reaction of chronic liver injury caused by various factors such as viral infection， alcohol， and chemical substances and is a key link in the progression of chronic liver diseases to liver cirrhosis and liver cancer. Liver macrophages are considered important mediators of liver injury and repair， and the polarization trend of macrophages has a bidirectional regulatory effect on liver fibrosis. This article reviews the role of different phenotypes of liver macrophages in the development and progression of liver fibrosis， in order to provide new ideas for the prevention and treatment of fibrosis.
- Liver Fibrosis,
- Macrophages,
- Cell Polarization

FullText(HTML)

References(39)

References

[1]	KOYAMA Y, BRENNER DA. Liver inflammation and fibrosis[J]. J Clin Invest, 2017, 127( 1): 55- 64. DOI: 10.1172/JCI88881.
[2]	LIU M, HU Y, YUAN Y, et al. γδT cells suppress liver fibrosis via strong cytolysis and enhanced NK cell-mediated cytotoxicity against hepatic stellate cells[J]. Front Immunol, 2019, 10: 477. DOI: 10.3389/fimmu.2019.00477.
[3]	KRENKEL O, TACKE F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017, 17( 5): 306- 321. DOI: 10.1038/nri.2017.11.
[4]	SICA A, MANTOVANI A. Macrophage plasticity and polarization: in vivo veritas[J]. J Clin Invest, 2012, 122( 3): 787- 795. DOI: 10.1172/JCI59643.
[5]	SHAPOURI-MOGHADDAM A, MOHAMMADIAN S, VAZINI H, et al. Macrophage plasticity, polarization, and function in health and disease[J]. J Cell Physiol, 2018, 233( 9): 6425- 6440. DOI: 10.1002/jcp.26429.
[6]	WANG L, ZHANG H, SUN L, et al. Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury[J]. J Nanobiotechnology, 2020, 18( 1): 38. DOI: 10.1186/s12951-020-00593-7.
[7]	XU F, GUO M, HUANG W, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH[J]. Redox Biol, 2020, 36: 101634. DOI: 10.1016/j.redox.2020.101634.
[8]	ZHAO S, MI Y, GUAN B, et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer[J]. J Hematol Oncol, 2020, 13( 1): 156. DOI: 10.1186/s13045-020-00991-2.
[9]	MA PF, GAO CC, YI J, et al. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice[J]. J Hepatol, 2017, 67( 4): 770- 779. DOI: 10.1016/j.jhep.2017.05.022.
[10]	YANG Y, YE YC, CHEN Y, et al. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors[J]. Cell Death Dis, 2018, 9( 8): 793. DOI: 10.1038/s41419-018-0818-0.
[11]	KAZANKOV K, JØRGENSEN S, THOMSEN KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 3): 145- 159. DOI: 10.1038/s41575-018-0082-x.
[12]	van der HEIDE D, WEISKIRCHEN R, BANSAL R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases[J]. Front Immunol, 2019, 10: 2852. DOI: 10.3389/fimmu.2019.02852.
[13]	KRENKEL O, TACKE F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017, 17( 5): 306- 321. DOI: 10.1038/nri.2017.11.
[14]	MATSUDA M, SEKI E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis[J]. Semin Liver Dis, 2020, 40( 3): 307- 320. DOI: 10.1055/s-0040-1708876.
[15]	SINGLA RD, WANG J, SINGLA DK. Regulation of Notch 1 signaling in THP-1 cells enhances M2 macrophage differentiation[J]. Am J Physiol Heart Circ Physiol, 2014, 307( 11): H1634- H1642. DOI: 10.1152/ajpheart.00896.2013.
[16]	WEI W, LI ZP, BIAN ZX, et al. Astragalus polysaccharide RAP induces macrophage phenotype polarization to M1 via the Notch signaling pathway[J]. Molecules, 2019, 24( 10): 2016. DOI: 10.3390/molecules24102016.
[17]	ZHENG S, ZHANG P, CHEN Y, et al. Inhibition of Notch signaling attenuates schistosomiasis hepatic fibrosis via blocking macrophage M2 polarization[J]. PLoS One, 2016, 11( 11): e0166808. DOI: 10.1371/journal.pone.0166808.
[18]	TRAVIS MA, SHEPPARD D. TGF-β activation and function in immunity[J]. Annu Rev Immunol, 2014, 32: 51- 82. DOI: 10.1146/annurev-immunol-032713-120257.
[19]	LU H, WU L, LIU L, et al. Quercetin ameliorates kidney injury and fibrosis by modulating M1/M2 macrophage polarization[J]. Biochem Pharmacol, 2018, 154: 203- 212. DOI: 10.1016/j.bcp.2018.05.007.
[20]	CHEN B, HUANG S, SU Y, et al. Macrophage Smad3 protects the infarcted heart, stimulating phagocytosis and regulating inflammation[J]. Circ Res, 2019, 125( 1): 55- 70. DOI: 10.1161/CIRCRESAHA.119.315069.
[21]	XIN P, XU X, DENG C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol, 2020, 80: 106210. DOI: 10.1016/j.intimp.2020.106210.
[22]	WANG F, ZHANG S, JEON R, et al. Interferon gamma induces reversible metabolic reprogramming of M1 macrophages to sustain cell viability and pro-inflammatory activity[J]. EBioMedicine, 2018, 30: 303- 316. DOI: 10.1016/j.ebiom.2018.02.009.
[23]	HU X, CHEN J, WANG L, et al. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation[J]. J Leukoc Biol, 2007, 82( 2): 237- 243. DOI: 10.1189/jlb.1206763.
[24]	HE Y, GAO Y, ZHANG Q, et al. IL-4 switches microglia/macrophage M1/M2 polarization and alleviates neurological damage by modulating the JAK1/STAT6 pathway following ICH[J]. Neuroscience, 2020, 437: 161- 171. DOI: 10.1016/j.neuroscience.2020.03.008.
[25]	GAO S, ZHOU J, LIU N, et al. Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13[J]. J Mol Cell Cardiol, 2015, 85: 131- 139. DOI: 10.1016/j.yjmcc.2015.04.025.
[26]	QUERO L, TIADEN AN, HANSER E, et al. miR-221-3p drives the shift of M2-macrophages to a pro-inflammatory function by suppressing JAK3/STAT3 activation[J]. Front Immunol, 2019, 10: 3087. DOI: 10.3389/fimmu.2019.03087.
[27]	QIAN M, WANG S, GUO X, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-‍κB pathways[J]. Oncogene, 2020, 39( 2): 428- 442. DOI: 10.1038/s41388-019-0996-y.
[28]	BAO L, LI X. MicroRNA-32 targeting PTEN enhances M2 macrophage polarization in the glioma microenvironment and further promotes the progression of glioma[J]. Mol Cell Biochem, 2019, 460( 1-2): 67- 79. DOI: 10.1007/s11010-019-03571-2.
[29]	HU J, HUANG CX, RAO PP, et al. Inhibition of microRNA-155 attenuates sympathetic neural remodeling following myocardial infarction via reducing M1 macrophage polarization and inflammatory responses in mice[J]. Eur J Pharmacol, 2019, 851: 122- 132. DOI: 10.1016/j.ejphar.2019.02.001.
[30]	DHAR D, BAGLIERI J, KISSELEVA T, et al. Mechanisms of liver fibrosis and its role in liver cancer[J]. Exp Biol Med(Maywood), 2020, 245( 2): 96- 108. DOI: 10.1177/1535370219898141.
[31]	PRADERE JP, KLUWE J, de MINICIS S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J]. Hepatology, 2013, 58( 4): 1461- 1473. DOI: 10.1002/hep.26429.
[32]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
[33]	BANSAL R, van BAARLEN J, STORM G, et al. The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis[J]. Sci Rep, 2015, 5: 18272. DOI: 10.1038/srep18272.
[34]	WATANABE Y, TSUCHIYA A, SEINO S, et al. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice[J]. Stem Cells Transl Med, 2019, 8( 3): 271- 284. DOI: 10.1002/sctm.18-0105.
[35]	LUO XY, MENG XJ, CAO DC, et al. Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes[J]. Stem Cell Res Ther, 2019, 10( 1): 16. DOI: 10.1186/s13287-018-1122-8.
[36]	WANG M, ZHANG M, FU L, et al. Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis[J]. Theranostics, 2020, 10( 1): 36- 49. DOI: 10.7150/thno.37301.
[37]	SONG WJ, LI Q, MO RYU, et al. TSG-6 released from intraperitoneally injected canine adipose tissue-derived mesenchymal stem cells ameliorate inflammatory bowel disease by inducing M2 macrophage switch in mice[J]. Stem Cell Res Ther, 2018, 9( 1): 91. DOI: 10.1186/s13287-018-0841-1.
[38]	TOSELLO-TRAMPONT AC, KRUEGER P, NARAYANAN S, et al. NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice[J]. Hepatology, 2016, 63( 3): 799- 812. DOI: 10.1002/hep.28389.
[39]	YUNNA C, MENGRU H, LEI W, et al. Macrophage M1/M2 polarization[J]. Eur J Pharmacol, 2020, 877: 173090. DOI: 10.1016/j.ejphar.2020.173090.

Relative Articles

[1]	Shuyang ZHANG, Yanzhen BI, Shousheng LIU, Sheng LIU, Yongning XIN. Differentially expressed microRNAs in plasma exosomes from patients with chronic hepatitis B or hepatitis B virus-related acute-on-chronic liver failure: A bioinformatics analysis[J]. Journal of Clinical Hepatology, 2023, 39(8): 1848-1856. doi: 10.3969/j.issn.1001-5256.2023.08.013
[2]	Committee of Minimally Invasive Therapy in Oncology， Chinese Anti-Cancer Association, Committee of Ablation Therapy in Oncology， Chinese Anti-Cancer Association. Chinese expert consensus on Co-Ablation System for the treatment of primary liver cancer （2023 edition）[J]. Journal of Clinical Hepatology, 2023, 39(12): 2793-2797.
[3]	Yao ZHANG, Kai ZHANG, Pengdong KANG, Chao MA. Research advances in microRNA-200c in pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(4): 961-964. doi: 10.3969/j.issn.1001-5256.2022.04.045
[4]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[5]	Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
[6]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[7]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[8]	Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
[9]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[10]	Zhang ShiWan, Yu XueQin, Chen Fang, Mei YiHan, Mei XiaoPing. Biological characteristics of exosome microRNA and its role in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2083-2086. doi: 10.3969/j.issn.1001-5256.2020.09.039
[11]	Cheng YaFei, Wang Bin, Wang ShiMing. Role of microRNAs in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1900-1904. doi: 10.3969/j.issn.1001-5256.2020.08.049
[12]	Wang ZhiXin, Gou Ping, Yu WenHao, Ren Li, Yang DanCaiRang, Wang HaiJiu, Fan HaiNing. Measurement and bioinformatics analysis of exosomes microRNAs in bile of hepatic alveolar echinococcosis patients with biliary tract invasion[J]. Journal of Clinical Hepatology, 2020, 36(9): 2045-2049. doi: 10.3969/j.issn.1001-5256.2020.09.027
[13]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[14]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[15]	Zhang YuRui. Correlation between microRNA-520a and clinicopathological features of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(4): 689-693. doi: 10.3969/j.issn.1001-5256.2017.04.018
[16]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[17]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
[20]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	张玉婷，李嘉泰，宋晓静，丁方回，岳平，闫少林，李俊峰，张立婷，李汛. 不同IgM水平的原发性胆汁性胆管炎患者治疗应答及预后特点分析. 胃肠病学和肝病学杂志. 2025(02): 250-253 .
2.	曹玫华，林欢. 泼尼松联合熊去氧胆酸对原发性胆汁性胆管炎合并自身免疫性肝炎的治疗效果. 深圳中西医结合杂志. 2024(19): 108-111 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (867) PDF downloads(81)